Fig. 1From: Pharmacology-based ranking of anti-cancer drugs to guide clinical development of cancer immunotherapy combinationsFlow chart of the search and elimination process for selection of drugs of interest. *PD-1/PD-L1 class of drugs, were preselected as they are considered as the backbone for combination studies. The final number of drugs selected is 20 (19 + anti-PD-1/PD-L1)Back to article page